Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
28. July 2025
3 min to read

AI-enhanced recognition of occlusions in acute coronary syndrome (AERO-ACS): a retrospective study

Overview


In a one‑year, single‑centre cohort of 217 cath‑lab patients (72 STEMI, 145 NSTEMI), the AERO‑ACS study tested PMcardio’s AI ECG against traditional ST‑elevation rules for detecting angiographic occlusion‑MI. The algorithm matched STEMI sensitivity (86.5 % vs 83.3 %) while raising specificity to 82.2 % (vs 66.0 %), achieved 100 % sensitivity in STEMI cases, and flagged occlusions linked to a 12‑fold higher in‑hospital mortality risk—suggesting more accurate triage with fewer unnecessary activations.

Published in: Coronary Artery Disease
Published on: 25 July 2025

Background

Artificial intelligence (AI) augmentation of ECG assessment has significant potential to improve patient outcomes in acute coronary syndrome.

Methods

We used a 1-year retrospective cohort of angiographic data from patients presenting with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). The device analyzed precatheterization ECGs to identify OMI, defined as a culprit vessel with thrombolysis In myocardial infarction (TIMI) 0–2 flow or TIMI 3 flow and peak cardiac troponin I > 10.0 ng/ml.

Results

A total of 217 patients were included: 72 STEMI (32%) and 145 NSTEMI (65%). Angiographic OMI was confirmed in 60 (83%) STEMI and 51 (35%) NSTEMI cases. The AI model achieved a sensitivity of 86.5%, specificity of 82.2%, and an area under the curve of 0.84. Traditional STEMI criteria had a sensitivity of 83.3% and a specificity of 66.0%. The AI model was 100% sensitive in detecting STEMI-OMI. The odds ratio for mortality in AI-detected OMI patients was 12.44 (1.56–98.98), unplanned readmissions 1.15 (0.53–2.51), and reduced ejection fraction at 1 year 0.24 (0.26–2.16).

Conclusion

The AI model demonstrated similar sensitivity but higher specificity than traditional STEMI criteria, improving OMI detection while reducing false positives. These findings suggest potential benefits in triage accuracy and resource utilization, but further prospective validation is needed to determine its clinical impact.

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Occlusion myocardial infarction: a revolution in acutecoronary syndrome

The 2025 ACC Guideline for the Management of Patients With Acute Coronary Syndromes claims that “Patients with NSTEMI may have a partially occluded coronary artery leading to subendocardial ischemia, while those with STEMI typically have a completely occluded vessel leading to transmural myocardial ischemia and infarction.” This is accompanied by a visual representation of a partially occlusive thrombus labeled ‘NSTEMI’ above an electrocardiogram (ECG) showing ST depression and T wave inversion, and a completely occlusive thrombus labeled ‘STEMI’ above an ECG showing ST elevation. This paradigm has remained despite two decades of angiographic and evidence-based ECG advances, which highlight the multiple reasons why a revolution in acute coronary syndrome (ACS) is needed, and has begun.

Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (PMcardio, queen of hearts)

This study aimed to measure physician accuracy for interpreting STEMI-equivalent and STEMI-mimic ECGs for catheterization laboratory activation (CLA) and compare their performance to a machine learning-based artificial intelligence algorithm, Queen of Hearts AI (QoH AI).

Join over 100,000 healthcare professionals who are already taking advantage of AI